An event is serious (FDA MedWatch definition) when the patient outcome is:deathlife-threateninghospitalisationdisabilitycongenital anomalyrequires intervention to prevent permanent impairment or damage

A 36-year-old man developed influenza A virus subtype H1N1-associated adult respiratory distress syndrome (ARDS) following steroid therapy.

The man, who had a history of autoimmune haemolytic anaemia (AIHA) and systemic lupus erythematosus, had achieved remission with steroid pulse therapy \[*drug and dosage details not stated*\]. He had been on maintenance therapy with ciclosporin 150 mg/day and prednisolone 20 mg/day \[*routes and duration of treatment not stated*\] when he was admitted to hospital due to recurrent AIHA. He received pulsed methylprednisolone 500 mg/day for 3 days \[*route not stated*\] followed by oral prednisolone 1 mg/kg/day. Two weeks later, prednisolone was tapered to 0.8 mg/kg/day over 2 weeks. Three days after spending a few hours out of hospital, he developed fever and mild cough. Empirical meropenem was started. As tests returned positive for influenza virus type A, he started receiving oseltamivir. His condition worsened and he experienced mild respiratory distress on day 2 of oseltamivir treatment. Imaging tests showed bilateral pulmonary infiltration and ground-glass opacities in both lung lobes. His leucocyte count decreased to 1700/µL and platelets to 76 × 10^3^/µL. CRP and KL-6 levels of 5.28 mg/dL and 515 U/L, respectively, confirmed interstitial lung inflammation. Meropenem was switched to ciprofloxacin. He received IV methylprednisolone 1 g/day for 3 days, followed by tapering, but repeat x-rays showed expansion of the ground-glass opacities. He required mechanical ventilation as he was diagnosed with ARDS. Bronchial washing cytology demonstrated diffuse alveolar damage. A nasopharyngeal swab was positive for pandemic (H1N1) 2009.

The man received IV peramivir, sivelestat and ulinastatin and underwent extracorporeal membrane oxygenation (ECMO) with continuous veno-venous haemodiafiltration. As his condition gradually improved, ECMO was discontinued and he was extubated. His daily dose of prednisolone was reduced to 20 mg/day. CT scan showed partial resolution of his lung findings. Two weeks later, he started to undergo rehabilitation without supplemental oxygen and was discharged from hospital.
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